BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38032438)

  • 21. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
    [No Abstract]   [Full Text] [Related]  

  • 22. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
    Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
    Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
    Lim SL; Havrilesky LJ; Habib AS; Secord AA
    Gynecol Oncol; 2019 May; 153(2):376-380. PubMed ID: 30718126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-analysis.
    Martins M; Santos-Sousa H; Araújo F; Nogueiro J; Sousa-Pinto B
    Ann Surg Oncol; 2022 Nov; 29(12):7528-7537. PubMed ID: 35930109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRS-HIPEC Prolongs Survival but is Not Curative for Patients with Peritoneal Carcinomatosis of Gastric Cancer.
    Boerner T; Graichen A; Jeiter T; Zemann F; Renner P; März L; Soeder Y; Schlitt HJ; Piso P; Dahlke MH
    Ann Surg Oncol; 2016 Nov; 23(12):3972-3977. PubMed ID: 27313067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
    Naffouje SA; O'Donoghue C; Salti GI
    J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal goblet cell carcinomas with peritoneal carcinomatosis: results from a single specialized center.
    Yu HH; Yonemura Y; Hsieh MC; Mizumoto A; Wakama S; Lu CY
    Cancer Manag Res; 2017; 9():513-523. PubMed ID: 29089784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant tumors in children: Initial experience in a single institution.
    Zhu Z; Chang X; Wang J; Yang S; Qin H; Yang W; Cheng H; Meng D; Wang H
    Front Surg; 2022; 9():1078039. PubMed ID: 36713659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
    Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence.
    Huang CQ; Min Y; Wang SY; Yang XJ; Liu Y; Xiong B; Yonemura Y; Li Y
    Oncotarget; 2017 Aug; 8(33):55657-55683. PubMed ID: 28903452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
    Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
    BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
    JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis.
    Rihuete Caro C; Manzanedo I; Pereira F; Carrion-Alvarez L; Serrano Á; Pérez-Viejo E
    Eur J Surg Oncol; 2018 Nov; 44(11):1805-1810. PubMed ID: 30087071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review.
    Chia CS; Seshadri RA; Kepenekian V; Vaudoyer D; Passot G; Glehen O
    Pleura Peritoneum; 2016 Jun; 1(2):67-77. PubMed ID: 30911610
    [No Abstract]   [Full Text] [Related]  

  • 39. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis.
    Ellison LM; Man Y; Stojadinovic A; Xin H; Avital I
    Chin J Cancer Res; 2017 Feb; 29(1):86-92. PubMed ID: 28373757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
    Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
    World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.